Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with... Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. 詳細を表示
Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Dual and synergistic signaling of IL-15 and IL-21 robustly augments NK and CD8 T cell responses Highlights importance of dual inhibition or activation for therapeutic approaches Equillium Inc...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0826 | -11.9710144928 | 0.69 | 0.735 | 0.5605 | 157241 | 0.63449253 | CS |
4 | -0.0926 | -13.2285714286 | 0.7 | 0.829899 | 0.5605 | 114311 | 0.69118671 | CS |
12 | -0.2026 | -25.012345679 | 0.81 | 1.5 | 0.5605 | 176805 | 0.89019324 | CS |
26 | -0.0836 | -12.0984081042 | 0.691 | 1.5 | 0.5605 | 155234 | 0.87363955 | CS |
52 | -0.1111 | -15.462769659 | 0.7185 | 3.25 | 0.5605 | 251068 | 1.32172789 | CS |
156 | -3.6026 | -85.5724465558 | 4.21 | 4.75 | 0.45 | 167334 | 1.36833184 | CS |
260 | -3.9326 | -86.6211453744 | 4.54 | 30.2 | 0.45 | 361796 | 10.58803529 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約